Ovulation Inducing Drugs Market on Track for Strong Growth, Estimated to Grow at 6.6% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

What Is the Expected CAGR for the Ovulation Inducing Drugs Market Through 2025?
In recent times, the market size for ovulation induction drugs has experienced robust growth. The market value is projected to increase from $4.42 billion in 2024 to $4.74 billion in 2025, implying a compound annual growth rate (CAGR) of 7.3%. The market expansion during the historic period can largely be ascribed to factors such as the formulation of clomiphene citrate, the launch of letrozole, regulatory endorsements and normalization, and the advent of ovulation prediction kits.

What's the Projected Size of the Global Ovulation Inducing Drugs Market by 2029?
The market size for ovulation-inducing drugs is anticipated to experience significant growth in the coming years. The projections show that it will expand to $6.12 billion by 2029 at a compound annual growth rate (CAGR) of 6.6%. Factors contributing to the growth during the projected period include changes in lifestyle, deferred childbearing, integration of digital health, increased market penetration, climbing rates of infertility, and tailored treatment plans. Key trends for the forecast period encompass individualized treatment methods, progress in reproductive endocrinology, non-invasive methods of fertility monitoring, increased demand for assisted reproductive technologies, and the development of innovative drug formulations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/ovulation-inducing-drugs-global-market-report

Top Growth Drivers in the Ovulation Inducing Drugs Industry: What's Accelerating the Market?
The surge in cases of female infertility is anticipated to instigate the expansion of the ovulation-inducing drug market. Female infertility is a biological issue that results in women not being able to get pregnant or sustain a pregnancy to full term. This is despite regular, unprotected intercourse extended over a lengthy timeframe of around a year or more. Ovulation-inducing medications are employed to manage this infertility, targeting the irregular or lack of ovulation. These medications stimulate the release of mature eggs by targeting the hormonal pathways involved in ovulation. As per the Centers for Disease Control and Prevention, a US government agency, it is projected that in 2022, there'll be 6.1 million women aged between 15-44 in the US who struggle with getting pregnant, making up 10% of all women. Moreover, according to CCRM Management Company LLC, a US-based health management company estimated that in June 2022, 1 in 4 couples worldwide experience infertility, which is increasing by 5-10% annually. Hence, the escalating prevalence of female infertility fuels the growth of the ovulation-inducing drug market. Ovulation Inducing Drugs Market Driver: Surge on Patients Seeking IVF in The Ovulation Inducing Drugs Market

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13256&type=smp

What Trends Will Shape the Ovulation Inducing Drugs Market Through 2029 and Beyond?
Leading entities in the ovulation-inducing drugs sector are working on groundbreaking drugs such as Cetrorelix acetate, which are securing approval for managing women experiencing controlled ovarian stimulation. Cetrorelix acetate for injection, otherwise known as cetrorelix, serves as a GnRH antagonist, that averts early ovulation in women going through in vitro fertilization (IVF). For example, in August 2022, Akorn Operating Company LLC, an American pharmaceutical firm, attained FDA approval for a generic form of cetrorelix acetate for injection, 0.25 mg (Cetrorelix). This signified the first AP-rated bioequivalent version of Merck Serono Cetrotide to be approved. Cetrorelix acetate functions as a GnRH antagonist by countering the effects of gonadotropin-releasing hormone. This hormone stimulates the pituitary gland to produce luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Additionally, it's employed to avert premature LH surges in women experiencing controlled ovarian stimulation to provide all eggs an opportunity for maturation.

What Are the Main Segments in the Ovulation Inducing Drugs Market?
The ovulation inducing drugs market covered in this report is segmented -

1) By Drug Class: Hormones, Therapeutics Drugs
2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
3) By End-User: Hospital, Homecare, Specialty Clinics, Other End-Users

Subsegments:
1) By Hormones: Gonadotropins, Clomiphene Citrate, Aromatase Inhibitors
2) By Therapeutic Drugs: Metformin, Letrozole, Bromocriptine

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13256&type=smp

Which Top Companies are Driving Growth in the Ovulation Inducing Drugs Market?
Major companies operating in the ovulation inducing drugs market report are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Abbvie Inc., Novartis AG, Bayer AG, Sanofi SA, Abbott Laboratories, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceutical Inc., Mylan N.V, Astellas Pharma Inc., Sun Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Dr Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Endo International Inc., Ferring Pharmaceuticals Inc., Lupin Limited, LIVZON Pharmaceutical Group Inc., Torrent Pharmaceuticals Ltd., Gedeon Richter PLC, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Zydus Pharmaceuticals (USA) Inc., Serum Institute of India Ltd., EMD Serono Inc., Cipla Inc.

Which Regions Will Dominate the Ovulation Inducing Drugs Market Through 2029?
North America was the largest region in the ovulation-inducing drugs market in 2024. The regions covered in the ovulation inducing drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13256

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.